A clinical trial to study the effect of drug inj. Histaglobulin in patients with chronic Skin allergy (urticaria)

"Effectiveness of Histoglobulin in producing long term remission in patients with chronic auto immune urticaria"

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/01/005447

Enrollment

Registered

2015-01-22

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Chronic Urticaria

Interventions

Intervention1: Injection Histaglobulin: Weekly subcutaneous injection of 1 ml Histaglobulin was administered for 8 weeks Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: Chronic urticaria Duration of lesions: 6 weeks or more Duration of lesions each day:less than 24 hours

Exclusion criteria

Exclusion criteria: 1.Physical urticaria 2.Drug-induced urticaria 3.Age less than 18 years 4.Pregnant & Lactating 5.Long term immunosuppressants

Design outcomes

Primary

Measure	Time frame
Urticaria activity score at six months of starting therapyTimepoint: Six months after starting therapy	—

Secondary

Measure	Time frame
Weekly reduction in Urticaria activity scoreTimepoint: Weekly for 8 weeks	—

Countries

India

Contacts

Public ContactRajesh Kumar Gurumoorthy

Sri Manakula Vinayagar Medical College and Hospital.

rkjip@yahoo.co.in9791709926

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026